PDCD1 and melanoma: reported that inhibiting FTO enabled the sensitivity of the response to anti-PD-1 therapy in vivo by mediating the regulation of PD-1, CXCR4, and SOX10 in melanoma (130), revealing a critical role of FTO inhibition in accelerating melanoma cell resistance to anti-PD-1 blockade (170).